Ticagrelor versus clopidogrel in patients with acute coronary ...

More documents

Recommendations

Info

Disclosures The PLATO trial was funded by AstraZeneca Dr. Held discloses research grants/support from: AstraZeneca, GlaxoSmithKline, Schering-Plough, Sanofi-Aventis, Pfizer, Bristol-Myers Squibb
Ticagrelor (AZD 6140): an oral reversibly binding P2Y 12 antagonist CABG HO N N N HO O N N H N F Ticagrelor is a cyclo-pentyltriazolo-pyrimidine (CPTP) OH S F • Direct acting – Not a pro-drug; does not require metabolic activation – Rapid onset of inhibitory effect on the P2Y 12 receptor – Greater inhibition of platelet aggregation than clopidogrel • Reversibly bound – Degree of inhibition reflects plasma concentration – Faster offset of effect than clopidogrel – Functional recovery of circulating platelets within ~48 hours
Page 1: CABG Ticagrelor versus clopidogrel
Page 5 and 6: Objectives CABG The objective of th
Page 7 and 8: Patient disposition CABG 18,624 pat
Page 9 and 10: Evaluations and invasive procedures
Page 11 and 12: Study medication pre- and post-CABG
Page 13 and 14: Time from CABG to primary endpoint:
Page 15 and 16: Time from CABG to CV death (CABG po
Page 17 and 18: Bleeding from time of CABG CABG Cha
Page 19 and 20: Limitations CABG • Retrospective

Ticagrelor versus clopidogrel in patients with acute coronary ...

Create successful ePaper yourself

Delete template?

Save as template?